DBLMSP2

DBLMSP2 (PF3D7_1036300) is a polymorphic merozoite surface protein of the Duffy binding-like (DBL) domain family whose activities center on erythrocyte engagement and host immune evasion during the blood stage (PMID:22843685, PMID:27226583). Its DBL domain adopts a canonical boomerang-shaped α-helical fold of three subdomains and binds human erythrocytes, an activity enhanced by metal cofactors; polymorphic residues cluster on the surface of subdomains 1 and 2 while the inter-subdomain cleft and the subdomain-3 groove are conserved and functionally important for receptor binding (PMID:22843685). Through a structurally distinct mode captured by cryo-EM, the same DBL domain avidly binds human IgM in a manner conserved across broadly diverged allelic classes; this IgM binding masks the protein from IgG immunoreactivity in patient sera and interferes with IgM-mediated complement activation, functioning as an immune shield without detectably altering red blood cell invasion (PMID:27226583, PMID:37156765). Expression of DBLMSP2 is restricted to a discrete schizont subpopulation that is positively regulated by GDV1 but is largely distinct from AP2-G-expressing schizonts and dispensable for sexual commitment and asexual growth (PMID:38530030). Genetic modulation of DBLMSP2, including copy-number changes and a C591S substitution, specifically alters parasite sensitivity to the structurally related antimalarials halofantrine, mefloquine, and lumefantrine (PMID:23587962).

1. 2012 High

   Establishing whether DBLMSP2 engages host cells defined its role as a merozoite surface receptor-binding protein and revealed the structural basis of that interaction.

   Evidence Crystal structure of the DBL domain at 2.09 Å with recombinant and native erythrocyte-binding assays and metal cofactor titration in P. falciparum

   PMID:22843685

   Open questions at the time

   • The erythrocyte receptor for DBLMSP2 was not identified
   • Functional consequence of erythrocyte binding for invasion or growth not resolved
   • Role of metal cofactor enhancement in vivo unknown
2. 2016 High

   Discovery that the DBL domain avidly binds human IgM across allelic classes reframed DBLMSP2 as an immune-evasion molecule that shields itself from the IgG response rather than a simple invasion ligand.

   Evidence Recombinant and transgenic-parasite binding assays, population genomics of >400 isolates, IgG immunoreactivity and invasion assays in P. falciparum

   PMID:27226583

   Open questions at the time

   • Molecular interface of the IgM interaction not defined at this stage
   • In vivo immune-shielding benefit not demonstrated
   • Relationship between IgM binding and erythrocyte binding unresolved
3. 2023 High

   Structural resolution of the DBLMSP2–IgM complex and a complement assay showed the interaction uses a distinct DBL–IgM mode and directly blocks complement activation, giving mechanistic teeth to the immune-shield model.

   Evidence High-resolution cryo-EM and in vitro complement activation assay in P. falciparum

   PMID:37156765

   Open questions at the time

   • Contribution of complement inhibition to parasite survival in the host not tested
   • Whether IgM binding and complement blockade operate on the merozoite surface in vivo not shown
4. 2013 High

   Genetic manipulation established that DBLMSP2 modulates parasite sensitivity to a specific chemical class of antimalarials, linking this surface protein to drug response and adaptive allele selection.

   Evidence Knockout, overexpression and C591S allele-swap lines with IC50 assays and growth competition under drug pressure in P. falciparum

   PMID:23587962

   Open questions at the time

   • Mechanism connecting a surface DBL protein to drug sensitivity is unknown
   • No molecular link between the C591S variant and drug handling defined
5. 2024 High

   Defining the transcriptional control and cellular expression pattern of DBLMSP2 placed it downstream of GDV1 in a discrete schizont subpopulation while decoupling it from AP2-G-driven sexual commitment.

   Evidence Conditional GDV1 overexpression, gdv1 truncation, SLI lines, IFA co-localisation with HA-AP2-G, and conversion/growth assays in P. falciparum

   PMID:38530030

   Open questions at the time

   • Biological purpose of the distinct DBLMSP2-positive schizont subpopulation unknown
   • Direct versus indirect regulation by GDV1 not distinguished

• The identity of the erythrocyte receptor and the mechanistic basis by which a surface DBL protein influences antimalarial drug sensitivity remain unresolved.
• No erythrocyte receptor identified
• No mechanism linking DBLMSP2 to halofantrine/mefloquine/lumefantrine handling
• Functional role of the GDV1-regulated DBLMSP2-positive subpopulation undefined